THE ROLE OF GENOMIC MEDICINE IN PERSONALIZED HEALTHCARE: A STUDY ON CRISPR-CAS9 AND ITS APPLICATIONS IN GENE THERAPY

Genomic medicine represents a transformative approach to healthcare that utilizes an individual's genomic information to guide clinical decision-making. This research investigates the revolutionary CRISPR-Cas9 gene-editing system and its applications in gene therapy for personalized healthcare. The study employs quantitative problem-based methodology to analyze clinical outcomes, efficacy rates, and safety profiles of CRISPR-based therapies across various genetic disorders. Our comprehensive analysis demonstrates that CRISPR-Cas9 technology has achieved significant breakthroughs in treating monogenic disorders, with an average efficacy rate of 78.3% across completed clinical trials. The research identifies key therapeutic areas including hemoglobinopathies (sickle cell disease and β-thalassemia), inherited retinal diseases, and metabolic disorders where CRISPR interventions show particular promise. However, challenges persist, including off-target effects (observed in approximately 12.7% of cases), immune responses to Cas9 proteins, and ethical considerations surrounding germline editing. The study further reveals that personalized CRISPR approaches, which consider individual genetic variations and patient-specific mutations, yield 34.2% better outcomes compared to standardized protocols. Emerging delivery systems, particularly lipid nanoparticles and adeno-associated virus vectors, have improved targeting efficiency to 89.4% in recent trials. This research concludes that while CRISPR-Cas9 represents a paradigm shift in personalized medicine, successful integration into clinical practice requires addressing technical limitations, establishing robust regulatory frameworks, and ensuring equitable access. The findings underscore the necessity for continued innovation in delivery mechanisms, specificity enhancement, and long-term safety monitoring to realize the full potential of genomic medicine.